Articles tagged with: Gilead Sciences

FDA approves a generic form of PrEP

published: June, 16, 2017 Written by // Guest Authors - Revolving Door Categories // African, Caribbean and Black, Social Media, As Prevention , Gay Men, Youth, Current Affairs, Treatment Guidelines -including when to start, Women, Revolving Door, International , Treatment, Guest Authors, Media

Sexual health advocates hope this will make widen access to PrEP, the medication that helps prevent people contracting HIV

FDA approves a generic form of PrEP

To read the complete article by David Hudson visit Gay Star News, here. The Food and Drug Administration (FDA) in the US has approved the first generic form of PrEP. PrEP is medication that can be taken by someone to prevent them becoming infected with HIV. It’s a daily pill of Truvada, produced by Gilead Sciences. Truvada is a combination of Emtricitabine and Tenofovir Disoproxil Fumarate The use of PrEP has been credited with driving down HIV infection rates in countries where it has

The capsid inhibitor—a new class to enter clinical trials

published: April, 13, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // African, Caribbean and Black, Social Media, As Prevention , Gay Men, CATIE, Youth, General Health, Treatment Guidelines -including when to start, Women, CATIE - HIV and Hep C Info Resource, Sexual Health, Health, International , Treatment, Media

From CATIE: "This finding suggests that the capsid inhibitor has potential for intermittent dosing in people—perhaps every one or two months."

The capsid inhibitor—a new class to enter clinical trials

Most approved anti-HIV drugs work by interfering with an enzyme and/or protein that is needed by HIV-infected cells to make new viruses. A journey through the cell The capsid is the name given to the proteins that surround HIV’s genetic material. Upon HIV attaching itself to a target cell of the immune system, the virus sends its genetic material (RNA) into the cell. As the genetic material is surrounded by the capsid, it is protected from detection by the cell’s internal sensors. The ca

From the Conference on Retroviruses and Opportunistic Infections (CROI) 2017; new drugs, new hope and possible timelines

published: April, 07, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , CATIE, Gay Men, Treatment Guidelines -including when to start, Research, CATIE - HIV and Hep C Info Resource, Treatment, Media

From CATIE, Sean R. Hosein reports on several new drugs that are in varying stages of development.

From the Conference on Retroviruses and Opportunistic Infections (CROI) 2017;  new drugs, new hope and possible timelines

Une version française est disponible ici. At the recent Conference on Retroviruses and Opportunistic Infections (CROI), which took place in Seattle from February 13 to 16, 2017, researchers presented data about new anti-HIV compounds in development, including the following: a new integrase inhibitor – bictegravir a new nuke (NRTI) – code-named GS-9131 a non-nuke (NNRTI) – doravirine a new protease inhibitor – code-named GS-PI1 a capsid inhibitor (a new cla

In the search for an HIV cure, David Evans explains “freedom” and how to better involve women & people of color

published: February, 21, 2017 Written by // Guest Authors - Revolving Door Categories // African, Caribbean and Black, Social Media, Women, Health, International , Revolving Door, Guest Authors, Media

From Betablog, Emily Newman reports on an ambitious HIV cure social science research project funded recently by Gilead Sciences.

In the search for an HIV cure, David Evans explains “freedom” and how to better involve women & people of color

To read the entire article by Emily Newman, visit Betablog, here. At an international AIDS Conference last year, David Evans, director of research advocacy at Project Inform, asked conference attendees to share their ideas about what an HIV cure—that worked for everyone and was freely available—would mean to them or the people they loved. “By far, the most common answer was ‘freedom,’” he said. “Whether it was freedom from stigma, from discrimination, or from knowing they would

Funders Concerned About AIDS (FCAA) report says philanthropic AIDS funding point highest since 2008

published: December, 29, 2016 Written by // Guest Authors - Revolving Door Categories // Social Media, Activism, Current Affairs, International , Revolving Door, Guest Authors

Global philanthropic funding up to $663 million but more resources, broader engagement needed to end epidemic

Funders Concerned About AIDS (FCAA) report says philanthropic AIDS funding point highest since 2008

Washington, D.C., December 5, 2016 – Funders Concerned About AIDS (FCAA), the leading voice on philanthropic resources for the global AIDS epidemic, today released its 14th annual Philanthropic Support to Address HIV/AIDS report. This year’s findings indicate that global philanthropic funding to fight the epidemic increased 10 percent from 2014, reaching $663 million, the highest level of funding since 2008. “Although the increase in philanthropic funding is encouraging, there is st

Why are HIV groups charging Gilead with bad behavior in new PrEP trial

published: November, 22, 2016 Categories // Activism, Social Media, As Prevention , Gay Men, Current Affairs, Treatment Guidelines -including when to start, Research, Health, International , Treatment

Anna Forbes and Marc-André LeBlanc are among a coalition of HIV activists and organizations from Europe and North America calling Gilead out on their bad corporate behavior. Here they present the story so far.

Why are HIV groups charging Gilead with bad behavior in new PrEP trial

This article originally appeared at TheBody.com, here. Gilead is not following the accepted standard for community engagement in its new pre-exposure prophylaxis (PrEP) trial, and we are among a coalition of HIV activists and organizations from Europe and North America calling them out on their bad corporate behavior. We root our criticism in the Good Participatory Practice (GPP) guidelines that were inspired, in part, by controversies in earlier PrEP trials. Truvada (FTC/TDF) is approve

NHS England loses appeal – it must consider providing PrEP

published: November, 18, 2016 Written by // Guest Authors - Revolving Door Categories // Activism, Social Media, As Prevention , Current Affairs, Treatment Guidelines -including when to start, Health, Revolving Door, International , Treatment, Guest Authors

Nonetheless NHS England may still try to put obstacles in the way of NHS provision of PrEP, as AIDSmap.com's Roger Pebody reports.

NHS England loses appeal – it must consider providing PrEP

Not all the UK press has been enthusiastic At the Court of Appeal in London, three judges just now confirmed that NHS England is responsible for providing PrEP. Key to the case is the fact that NHS England already commissions post-exposure prophylaxis (PEP) which is not substantially different to pre-exposure prophylaxis (PrEP). Nonetheless NHS England may still try to put obstacles in the way of NHS provision of PrEP. As Lord Justice Underhill wrote, the judgement “does not mean tha

HIV drug costs: potential for 90% reduction in costs coming soon?

published: November, 11, 2016 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Conferences, Treatment Guidelines -including when to start, Health, International , Revolving Door, Treatment, Guest Authors

Insurers in the United States are liable to pay up to four times the price paid by the UK’s NHS for branded antiretrovirals. From AIDSmap.com, Keith Alcorn of thebody.com on the need for more pricing transparency.

HIV drug costs: potential for 90% reduction in costs coming soon?

This article by Keith Alcorn previously appeared at AIDSmap.com, here. The costs of making drugs to treat viral hepatitis, HIV and tuberculosis (TB) are now so low that each disease could be treated for less than $90, Dr Andrew Hill of St Stephen’s AIDS Trust told the opening plenary of the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) on Sunday in Glasgow. The cost of generic drugs to cure TB is already below $90 for a six-month treatment course, and some anti

High Court rules NHS England is responsible for funding PrEP

published: August, 03, 2016 Written by // Guest Authors - Revolving Door Categories // Social Media, Gay Men, Current Affairs, General Health, Treatment Guidelines -including when to start, Sexual Health, Health, International , Revolving Door, Legal, Treatment, Guest Authors

The ruling does not mean PrEP will succeed as a candidate for funding. From AIDSmap, Keith Alcorn reports

High Court rules NHS England is responsible for funding PrEP

This article by Keith Alcorn previously appeared at AIDSmap.com here.   A judicial review in the High Court has ruled that NHS England is responsible for funding pre-exposure prophylaxis (PrEP) and decisively rebutted all the arguments used by NHS England to avoid paying for the use of PrEP. NHS England said today in response that the High Court ruling does not mean the medication will end up being funded by the NHS, and warned today that manufacturer Gilead Sciences now faces a bli

Coinfected with HIV and Hep C? Time to party like it’s 1996

published: March, 23, 2014 Written by // Guest Authors - Revolving Door Categories // Health, Revolving Door, Treatment, Guest Authors, Living with HIV

Benjamin Ryan writes in POZ about much improved treatment options for people living with HIV and HepC

Coinfected with HIV and Hep C? Time to party like it’s 1996

This article first appeared in POZ magazine here.    As hepatitis C treatment undergoes a revolution akin to the introduction of HIV antiretrovirals, the doors are swinging wide open for people coinfected with HIV to be cured of hep C. If you think that having HIV means you can’t be cured of a coinfection with hepatitis C, then think again. If you think the only way to rid yourself of the hepatitis C virus (HCV) and to spare your liver of its damaging consequences is to undergo a year of